https://abinhibitors.com/index.....php/outcomes-of-emi
The trial's registration in the Chinese Clinical Trial Registry is referenced by registration number ChiCTR1900022568. In heavily pretreated HER2-negative metastatic breast cancer (MBC) patients, who had prior exposure to anthracyclines and taxanes, the administration of PLD (Duomeisu) at 40 mg/m2 every four weeks proved both effective and well-tolerated, offering a potentially via
Like
Comment
Share
